{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:33Z","timestamp":1791348813564,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":2877,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s13311-015-0368-4","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T10:35:03Z","timestamp":1436783703000},"page":"874-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons"],"prefix":"10.1016","volume":"12","author":[{"given":"Leslie","family":"Matalonga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Tort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X\u00e8nia","family":"Ferrer-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Garcia-Villoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Josep","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Ribes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0368-4_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0968-0004(03)00176-2","article-title":"New insights into the formation of active nonsense-mediated decay complexes","volume":"28","author":"Singh","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1007\/s13311-015-0368-4_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.molmed.2006.05.005","article-title":"Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges","volume":"12","author":"Kuzmiak","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1007\/s13311-015-0368-4_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/438726a","article-title":"Nonsense mutations: running the red light","volume":"438","author":"Ainsworth","year":"2005","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0368-4_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0300-9084(72)80179-2","article-title":"The role of lysosomes in the pathogeny of storage diseases","volume":"54","author":"Hers","year":"1972","journal-title":"Biochimie"},{"key":"10.1007\/s13311-015-0368-4_bib5","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2001, pp. 3421-3452."},{"key":"10.1007\/s13311-015-0368-4_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1152\/physrev.1976.56.1.57","article-title":"Toward enzyme therapy for lysosomal storage diseases","volume":"56","author":"Desnick","year":"1976","journal-title":"Physiol Rev"},{"key":"10.1007\/s13311-015-0368-4_bib7","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.2174\/138161211797247578","article-title":"Gene therapy for lysosomal storage diseases: progress, challenges and future prospects","volume":"17","author":"Seregin","year":"2011","journal-title":"Curr Pharm"},{"key":"10.1007\/s13311-015-0368-4_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-014-9701-z","article-title":"Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators","volume":"37","author":"Muntau","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-015-0368-4_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000343086","article-title":"Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease","volume":"3","author":"P\u00e9rez","year":"2012","journal-title":"Mol Syndromol"},{"key":"10.1007\/s13311-015-0368-4_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.gt.3302211","article-title":"Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment","volume":"11","author":"Bidou","year":"2004","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-015-0368-4_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymgme.2013.12.007","article-title":"Long-term nonsense suppression therapy moderates MPS I-H disease progression","volume":"111","author":"Gunn","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1007\/s13311-015-0368-4_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/humu.22547","article-title":"Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients","volume":"35","author":"Micale","year":"2014","journal-title":"Hum Mutat"},{"issue":"Suppl. A","key":"10.1007\/s13311-015-0368-4_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/ejpn.2000.0436","article-title":"Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis","volume":"5","author":"Sleat","year":"2001","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0368-4_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmb.2004.03.012","article-title":"alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients","volume":"338","author":"Hein","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-015-0368-4_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddu428","article-title":"The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy","volume":"24","author":"Miller","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0368-4_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/bi00568a029","article-title":"Triphasic concentration effects of gentamicin on activity and misreading in protein s\u00edntesis","volume":"18","author":"Tai","year":"1979","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-015-0368-4_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"10.1007\/s13311-015-0368-4_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0368-4_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2011.10.005","article-title":"The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse","volume":"105","author":"Wang","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1007\/s13311-015-0368-4_bib20","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"key":"10.1007\/s13311-015-0368-4_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0368-4_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bbrc.2012.09.133","article-title":"Treatment of a methylmalonyl-CoA mutase stop codon mutation","volume":"427","author":"Buck","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-015-0368-4_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10545-012-9521-y","article-title":"Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI","volume":"36","author":"Bartolomeo","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-015-0368-4_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002608","article-title":"Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin","volume":"8","author":"Floquet","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-015-0368-4_bib25","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.38.11.2517","article-title":"Proposed molecular and cellular mechanism for aminoglycoside ototoxicity","volume":"38","author":"Hutchin","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s13311-015-0368-4_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s13311-015-0368-4_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10545-010-9265-5","article-title":"PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation","volume":"34","author":"Tan","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-015-0368-4_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-8981(78)90510-7","article-title":"Study of influence of sex and age on human serum lysosomal enzymes by using 4-methylumbelliferyl substrates","volume":"90","author":"Annunziata","year":"1978","journal-title":"Clin Chim Acta"},{"key":"10.1007\/s13311-015-0368-4_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-61779-080-5_19","article-title":"Cellular chemosensitivity assays: an overview","volume":"731","author":"Sumantran","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1007\/s13311-015-0368-4_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/glycob\/cwg082","article-title":"Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies","volume":"13","author":"Barbosa","year":"2003","journal-title":"Glycobiology"},{"key":"10.1007\/s13311-015-0368-4_bib31","doi-asserted-by":"crossref","first-page":"28995","DOI":"10.1074\/jbc.270.48.28995","article-title":"A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro","volume":"270","author":"Carter","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-015-0368-4_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/88099","article-title":"A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition","volume":"19","author":"Noensie","year":"2001","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-015-0368-4_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/abio.2000.4753","article-title":"Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods","volume":"285","author":"Schmittgen","year":"2000","journal-title":"Anal Biochem"},{"key":"10.1007\/s13311-015-0368-4_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"10.1007\/s13311-015-0368-4_bib35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","article-title":"Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm","volume":"4","author":"Kumar","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1007\/s13311-015-0368-4_bib36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1007\/s13311-015-0368-4_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060478","article-title":"Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression","volume":"8","author":"Keeling","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0368-4_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.molmed.2006.06.001","article-title":"Stop-codon read-through for patients affected by a lysosomal storage disorder","volume":"12","author":"Brooks","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1007\/s13311-015-0368-4_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice","volume":"104","author":"Barton-Davis","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0368-4_bib40","doi-asserted-by":"crossref","first-page":"15676","DOI":"10.1073\/pnas.0405155101","article-title":"Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons","volume":"101","author":"Lai","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0368-4_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jmg.39.1.62","article-title":"In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients","volume":"39","author":"Grayson","year":"2002","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-015-0368-4_bib42","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0368-4_bib43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0368-4_bib44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nbt0913-771","article-title":"Doubts raised over \u2018read-through\u2019 Duchenne drug mechanism","volume":"31","author":"Sheridan","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-015-0368-4_bib45","unstructured":"Cooper GM. The cell: a molecular approach. 2nd ed. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK9876\/ (accessed 26 June 2015)."},{"key":"10.1007\/s13311-015-0368-4_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal storage diseases\u2013the horizon expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0368-4_bib47","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/nar\/30.9.2011","article-title":"Predominance of six different hexanucleotide recoding signals 3' of read-through stop codons","volume":"30","author":"Harrell","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1007\/s13311-015-0368-4_bib48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/1531-8249(200008)48:2<164::AID-ANA5>3.0.CO;2-B","article-title":"Sequence specificity of aminoglycoside-induced stop condon readthrough: potencial implications for treatment of Duchenne muscular dystrophy","volume":"48","author":"Howard","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0368-4_bib49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrm3454","article-title":"NMD: a multifaceted response to premature translational termination","volume":"13","author":"Kervestin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-015-0368-4_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(03)00050-2","article-title":"Glutamine is incorporated at the nonsense codons UAG and UAA in a suppressor-free Escherichia coli strain","volume":"1627","author":"Nilsson","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-015-0368-4_bib51","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2011.05.021","article-title":"Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients","volume":"104","author":"Sarkar","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1007\/s13311-015-0368-4_bib52","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/humu.22047","article-title":"Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia","volume":"33","author":"S\u00e1nchez-Alcudia","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1007\/s13311-015-0368-4_bib53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10545-013-9602-6","article-title":"In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria","volume":"36","author":"Ho","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-015-0368-4_bib54","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.pupt.2013.01.007","article-title":"Ataluren: a \u2018no-nonsense\u2019 approach for pulmonary diseases","volume":"26","author":"Loudon","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1007\/s13311-015-0368-4_bib55","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgme.2009.08.002","article-title":"Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation","volume":"99","author":"Wang","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1007\/s13311-015-0368-4_bib56","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/cmdc.201402208","article-title":"Discovery of natural products possessing selective eukaryotic readthrough activity: 3-epi-deoxynegamycin and its leucine adduct","volume":"9","author":"Taguchi","year":"2014","journal-title":"ChemMedChem"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0368-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300819X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300819X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0368-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:41:31Z","timestamp":1761806491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300819X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S187874792300819X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0368-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0368-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}